A prospective study of HIV disease progression in female and male drug users

Mayris P. Webber, Ellie Schoenbaum, Marc N. Gourevitch, Donna Buono, Robert S. Klein

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Objective: To compare HIV disease progression and mortality in a cohort of female and male drug users. Design: A prospective cohort study of 222 HIV-seropositive women and 302 HIV-seropositive men who attended a hospital-affiliated methadone maintenance program with on-site primary care. Methods: Regression slopes of CD4+ cell decline were compared using the two sample t-test, and the distribution of AIDS-defining illnesses evaluated by Mantel-Haenszel χ2 test. Time to AIDS-defining clinical conditions and death were compared using the Kaplan-Meier log-rank test. Multivariate estimates of progression to clinical AIDS or death, for all participants, stratified by sex, were derived from Cox proportional hazards models. Results: Ninety-five persons (43 women and 52 men) developed AIDS-defining conditions. Analyses of the rates of CD4+ cell decline, the distribution of first AIDS-defining illnesses, and the time to clinical AIDS did not differ by sex. In the multivariate model, sex was not associated with an AIDS outcome, whereas crack-cocaine use [hazards ratio (HR), 1.815; 95% confidence interval (CI), 1.151-2.863], CD4+ cell count (100 x 106/l; HR, 0.589; 95% CI, 0.511-0.679), and two or more HIV-related symptoms (HR, 1.702; 95% CI, 1.125-2.576) were associated. Mortality rates 18.71 per 100 person-years in women and 9.85 per 100 person-years in men) were similar, using univariate or multivariate methods. Conclusions: There was little difference in clinical outcomes or mortality between HIV-seropositive female and male drug users with access to primary care. However, crack-cocaine use was independently associated with progression to clinical AIDS.

Original languageEnglish (US)
Pages (from-to)257-262
Number of pages6
JournalAIDS
Volume13
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Drug Users
Disease Progression
Acquired Immunodeficiency Syndrome
HIV
Prospective Studies
Crack Cocaine
Confidence Intervals
Mortality
Primary Health Care
Methadone
CD4 Lymphocyte Count
Proportional Hazards Models
Cohort Studies

Keywords

  • Crack cocaine
  • Drug users
  • Opportunistic infections
  • Progression
  • Risk factors
  • Women

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A prospective study of HIV disease progression in female and male drug users. / Webber, Mayris P.; Schoenbaum, Ellie; Gourevitch, Marc N.; Buono, Donna; Klein, Robert S.

In: AIDS, Vol. 13, No. 2, 1999, p. 257-262.

Research output: Contribution to journalArticle

Webber, Mayris P. ; Schoenbaum, Ellie ; Gourevitch, Marc N. ; Buono, Donna ; Klein, Robert S. / A prospective study of HIV disease progression in female and male drug users. In: AIDS. 1999 ; Vol. 13, No. 2. pp. 257-262.
@article{7a46450407e5468d804a56c84e26945a,
title = "A prospective study of HIV disease progression in female and male drug users",
abstract = "Objective: To compare HIV disease progression and mortality in a cohort of female and male drug users. Design: A prospective cohort study of 222 HIV-seropositive women and 302 HIV-seropositive men who attended a hospital-affiliated methadone maintenance program with on-site primary care. Methods: Regression slopes of CD4+ cell decline were compared using the two sample t-test, and the distribution of AIDS-defining illnesses evaluated by Mantel-Haenszel χ2 test. Time to AIDS-defining clinical conditions and death were compared using the Kaplan-Meier log-rank test. Multivariate estimates of progression to clinical AIDS or death, for all participants, stratified by sex, were derived from Cox proportional hazards models. Results: Ninety-five persons (43 women and 52 men) developed AIDS-defining conditions. Analyses of the rates of CD4+ cell decline, the distribution of first AIDS-defining illnesses, and the time to clinical AIDS did not differ by sex. In the multivariate model, sex was not associated with an AIDS outcome, whereas crack-cocaine use [hazards ratio (HR), 1.815; 95{\%} confidence interval (CI), 1.151-2.863], CD4+ cell count (100 x 106/l; HR, 0.589; 95{\%} CI, 0.511-0.679), and two or more HIV-related symptoms (HR, 1.702; 95{\%} CI, 1.125-2.576) were associated. Mortality rates 18.71 per 100 person-years in women and 9.85 per 100 person-years in men) were similar, using univariate or multivariate methods. Conclusions: There was little difference in clinical outcomes or mortality between HIV-seropositive female and male drug users with access to primary care. However, crack-cocaine use was independently associated with progression to clinical AIDS.",
keywords = "Crack cocaine, Drug users, Opportunistic infections, Progression, Risk factors, Women",
author = "Webber, {Mayris P.} and Ellie Schoenbaum and Gourevitch, {Marc N.} and Donna Buono and Klein, {Robert S.}",
year = "1999",
doi = "10.1097/00002030-199902040-00014",
language = "English (US)",
volume = "13",
pages = "257--262",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A prospective study of HIV disease progression in female and male drug users

AU - Webber, Mayris P.

AU - Schoenbaum, Ellie

AU - Gourevitch, Marc N.

AU - Buono, Donna

AU - Klein, Robert S.

PY - 1999

Y1 - 1999

N2 - Objective: To compare HIV disease progression and mortality in a cohort of female and male drug users. Design: A prospective cohort study of 222 HIV-seropositive women and 302 HIV-seropositive men who attended a hospital-affiliated methadone maintenance program with on-site primary care. Methods: Regression slopes of CD4+ cell decline were compared using the two sample t-test, and the distribution of AIDS-defining illnesses evaluated by Mantel-Haenszel χ2 test. Time to AIDS-defining clinical conditions and death were compared using the Kaplan-Meier log-rank test. Multivariate estimates of progression to clinical AIDS or death, for all participants, stratified by sex, were derived from Cox proportional hazards models. Results: Ninety-five persons (43 women and 52 men) developed AIDS-defining conditions. Analyses of the rates of CD4+ cell decline, the distribution of first AIDS-defining illnesses, and the time to clinical AIDS did not differ by sex. In the multivariate model, sex was not associated with an AIDS outcome, whereas crack-cocaine use [hazards ratio (HR), 1.815; 95% confidence interval (CI), 1.151-2.863], CD4+ cell count (100 x 106/l; HR, 0.589; 95% CI, 0.511-0.679), and two or more HIV-related symptoms (HR, 1.702; 95% CI, 1.125-2.576) were associated. Mortality rates 18.71 per 100 person-years in women and 9.85 per 100 person-years in men) were similar, using univariate or multivariate methods. Conclusions: There was little difference in clinical outcomes or mortality between HIV-seropositive female and male drug users with access to primary care. However, crack-cocaine use was independently associated with progression to clinical AIDS.

AB - Objective: To compare HIV disease progression and mortality in a cohort of female and male drug users. Design: A prospective cohort study of 222 HIV-seropositive women and 302 HIV-seropositive men who attended a hospital-affiliated methadone maintenance program with on-site primary care. Methods: Regression slopes of CD4+ cell decline were compared using the two sample t-test, and the distribution of AIDS-defining illnesses evaluated by Mantel-Haenszel χ2 test. Time to AIDS-defining clinical conditions and death were compared using the Kaplan-Meier log-rank test. Multivariate estimates of progression to clinical AIDS or death, for all participants, stratified by sex, were derived from Cox proportional hazards models. Results: Ninety-five persons (43 women and 52 men) developed AIDS-defining conditions. Analyses of the rates of CD4+ cell decline, the distribution of first AIDS-defining illnesses, and the time to clinical AIDS did not differ by sex. In the multivariate model, sex was not associated with an AIDS outcome, whereas crack-cocaine use [hazards ratio (HR), 1.815; 95% confidence interval (CI), 1.151-2.863], CD4+ cell count (100 x 106/l; HR, 0.589; 95% CI, 0.511-0.679), and two or more HIV-related symptoms (HR, 1.702; 95% CI, 1.125-2.576) were associated. Mortality rates 18.71 per 100 person-years in women and 9.85 per 100 person-years in men) were similar, using univariate or multivariate methods. Conclusions: There was little difference in clinical outcomes or mortality between HIV-seropositive female and male drug users with access to primary care. However, crack-cocaine use was independently associated with progression to clinical AIDS.

KW - Crack cocaine

KW - Drug users

KW - Opportunistic infections

KW - Progression

KW - Risk factors

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=0033047562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033047562&partnerID=8YFLogxK

U2 - 10.1097/00002030-199902040-00014

DO - 10.1097/00002030-199902040-00014

M3 - Article

C2 - 10202832

AN - SCOPUS:0033047562

VL - 13

SP - 257

EP - 262

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -